Summary
A mid-size, top 5 European pharmaceutical company engaged PRA in a global Phase III study in 20 countries on patients with advanced breast cancer previously treated with or resistant to airmaximus an anthracycline and who are taxane resistant. By identifying optimal sites in in Russia, Ukraine, Belarus, and Estonia, PRA recruited 318 patients at 25 sites, compared to 450+ patients at 150 sites in Rest of World (ROW).
Register to download
Optimal Recruitment Strategies
You may also be interested in:
Publication
Surviving isn't Thriving: FDA RACE for Children Act brings hope for curing childhood cancer
With difficulties in research for pediatric cancer treatments the FDA RACE for Children Act brings hope for curing childhood cancer, and saving the…
Blog
Ask the Experts: How Do Blood Cancers Affect Populations Differently?
Blood cancer research has shown improvements in early detection and treatment advancements, which are associated with increased survival. However,…
Newsletter
Industry Watch
We wrap up the final week of August with news of exciting scientific advancements that have the potential to help develop therapies to prevent…